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CLINICAL FACTORS ASSOCIATED WITH SERUM COPPER CONCENTRATION
IN PATIENTS ON HEMODIALYSIS
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Nobuo Hashimoto
H. N. Medic Kitahiroshima, Kitahiroshima, Hokkaido, Japan
It is well known that renal insufﬁciency inﬂuences trace element
metabolism. In particular, patients treated with hemodialysis (HD) are at
higher risk for both deﬁciency and excess of trace elements. However,
derangements of serum trace element levels reported by previous studies
were sometimes inconsistent. In addition, harmful effects by trace element
derangements seem quite unclear.
In this cross-sectional study, we examined clinical factors associated
with serum copper levels in patients treated with HD for more than or
equal to 6 months.
In 49 patients (male : female ¼29 : 20, age 71 7 10 years, HD duration
84 7 71 months), the mean value of serum copper was 93.8 7 16.2 mg/dL.
In univariate analysis, there were no signiﬁcant correlation between serum
copper levels and patient’s age, sex, HD duration, the presence of diabetes
mellitus, serum albumin levels, and body mass index. Serum copper levels
signiﬁcantly correlated with serum levels of high-sensitivity C-reactive
protein (hs-CRP; r¼0.474, P¼0.001) and malondialdehyde-low-density
lipoprotein (r¼0.371, P¼0.009). It was notable that serum copper levels
tended to be lower in those treated with higher dose of sevelamer
hydrochloride (r¼0.255, P¼0.07). In multivariate analysis, hs-CRP
remained to be an independent determinant of serum copper levels.
We showed signiﬁcant association of serum copper levels with
inﬂammation and oxidative stress in HD patients. Further studies are
required to investigate whether sevelamer may improve serum copper
levels, inﬂammation, and oxidative stress.
http://dx.doi.org/10.1016/j.krcp.2012.04.41087
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Nutritional status is the most important factor which guarantees long
survival with higher quality of life on chronic dialysis patients. Various
procedures for evaluating nutritional status have been proposed but the
standard of them has not been established. We modiﬁed the MIS sheet, which
was originally established by Kalantar-Zadeh, by adding some parameters as
CRP, nPCR and the dialysis prescription on the same sheet.
We have performed NST activity using the modiﬁed MIS sheet twice a year
for recent 6 years. We categorize the patients into the next three groups based
on total point of MIS; Normal, Mild malnourished and moderately/severely
malnourished. The patient survival in each group could be clearly identiﬁed
from each other. The causes of malnutrition were categorized as inﬂammatory
type, mal-dietary type and mixed type. Therapeutic interventions were
inducted for each type; those were a treatment for pyorrhea, foot care and a
dialysis prescription change. Dietitians interviewed the patients with mal-
dietary type malnutrition and their families. Every six months, we repeatedly
evaluated the nutritional status of the patients and determined whether our
interventions had succeeded.
Our modiﬁed MIS sheet is not only a screening tool but a practical tool by
which we can make a therapeutic plan for various types of malnutrition.
Our preliminary results clariﬁed that the interventions derived from the
MIS system could signiﬁcantly improve the total score of MIS. In conclusion
the modiﬁed MIS sheet is desirable for a daily NST activity on chronic dialysis
patients.
http://dx.doi.org/10.1016/j.krcp.2012.04.41188
PROTEIN CATABOLIC RATE SHOULD BE NORMALIZED BY IDEAL BODY
WEIGHT NOT BY POST-DIALYSIS BODY WEIGHT.
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Protein catabolic rate (PCR) is calculated by urea kinetic model thorough
the dialysis session and it is recognized as expressing the protein intake inthe steady state of dialysis patients. PCR is generally normalized by post-
dialysis body weight (BW), expressed as nPCR, however, most dietary
guidelines for protein intake are documented as PCR normalized by ideal
BW (iPCR). We evaluated which is better nPCR or iPCR to estimate the
impact on the patient survival and to use it for dietary education for
dialysis patients.
119 chronic dialysis patients whose dialysis vintages were longer than
3 years were selected into this study. The mean age of them was 62.4years
old and the mean dialysis vintage was 115.4 months. The patients were
divided into 4 groups by each PCR value as less than 0.7, 0.7– 0.9, 0.9–1.1,
greater than 1.1 g/Kg/day. Kaplan-Meier analysis was conducted to
evaluate the 5–year patient survival in each PCR method. The difference in
the patient survival between 4 groups in each PCR method was evaluated
by Log-rank test.
Among 119 patients 30 patients died and 9 patients were censored out,
and the overall 5-year survival rate was 74.4%. There were no signiﬁcant
differences between 4 groups in nPCR. However, a signiﬁcant risk in the
group less than 0.7 g/Kg/day and a signiﬁcant beneﬁt in the group greater
than 1.1 g/Kg/day were observed in iPCR. Both nPCR and iPCR were not
independent signiﬁcant risk factor on the patient survival. Only age and the
serum level of CRP were signiﬁcant risk factor. We concluded the PCR
should be normalized by ideal BW not by post-dialysis BW.
http://dx.doi.org/10.1016/j.krcp.2012.04.41289
EFFECTS OF SOY CONSUMPTION ON SERUM LIPIDS AND APOPROTEINS
IN PERITONEAL DIALYSIS PATIENTS: A RANDOMIZED
CONTROLLED TRIAL
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Lipid abnormalities, particularly high serum concentration of
lipoprotein(a) [Lp(a)], are one of the major risk factors for cardiovascular
disease (CVD) in peritoneal dialysis (PD) patients. The present study was
designed to investigate the effects of soy consumption on serum lipids
and apoproteins, especially Lp(a), in PD patients .This study was a
randomized clinical trial in which 40 PD patients (20 males, 20 females)
were randomly assigned to either the soy or the control group. Patients
in the soy group received 28 g/day textured soy ﬂour (containing 14 g of
soy protein) for 8 weeks, whereas patients in the control group received
their usual diet, without any soy. At baseline and the end of week 8 of
the study, 5 mL of blood was collected from each patient after a 12- to
14-hour fast and serum triglyceride, total cholesterol, low density
lipoprotein-cholesterol (LDL-C), high density lipoprotein-cholesterol
(HDL-C), apoprotein B100 (apo B100) apoprotein A (apo AI), and
Lp(a) were measured.
In the present study, serum Lp(a) concentrations were above the
normal range in 86% of the PD patients. Mean serum Lp(a) concentration
was reduced signiﬁcantly, by 41%, in the soy group at the end of week
8 compared to baseline (p o 0.01); the reduction was also signiﬁcant
compared to the control group ( p o 0.05). During the study, mean
serum Lp(a) concentration did not change signiﬁcantly in the control
group. There were no signiﬁcant differences between the two groups in
mean changes in serum triglyceride, total cholesterol, HDL-C, LDL-C,
apoB100, or apoAI.
The results of our study indicate that soy consumption reduces serum
Lp(a) concentration, which is a risk factor for cardiovascular disease in
peritoneal dialysis patients.
http://dx.doi.org/10.1016/j.krcp.2012.04.41390
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Patients with end-stage renal disease (ESRD) often experience secondary
bone and mineral disorder requiring treatment with phosphate-binder (PB)
medications, vitamin D sterols, and calcimimetics. Ferric citrate is an oral,
iron-based PB in clinical development that has been shown to reduce
serum phosphorus while increasing serum ferritin and transferrin
saturation (TSAT) in ESRD patients. In a Phase 2 study, patients receiving
